Dereke Jonatan, Nilsson Charlotta
Department of Clinical Sciences, Diabetes Research Laboratory, Lund University, Lund, Sweden.
Department of Pediatrics, Department of Clinical Sciences, Helsingborg Hospital, Lund University, S- 251 87 Helsingborg, Sweden.
J Diabetes Metab Disord. 2022 Jul 7;21(2):1427-1432. doi: 10.1007/s40200-022-01075-3. eCollection 2022 Dec.
Type 1 diabetes is an autoimmune disease that often develops during childhood. Complications such as retinopathy often occur during the course of the disease. Studies to identify possible predictors of complications in type 1 diabetes are needed; in particular markers able to identify risk of complications long before they occur. The first aim of this study was to investigate plasma levels of sCD163, sST2 and Gal-3 at diagnosis of type 1 diabetes in children and adolescents. The second aim was to study their correlation to HbA1c in this study cohort.
Patients (n = 242, 0-18 years) with type 1 diabetes, at Helsingborg's Hospital were included in this study and circulating levels of sCD163, sST2 and Gal-3 were investigated in plasma using commercially available DuoSet ELISA and supplementary ancillary kit.
Circulating sCD163 was significantly higher at diagnosis compared to after diagnosis (666 ± 318ng/ml and 505 ± 223ng/ml respectively; p < 0.001). Also sST2 was significantly higher (18.2 [12.7-25.6] ng/ml respectively 9.1 [6.3-13.5] ng/ml (p < 0.001), but Gal-3 levels did not differ from onset of diabetes to after diagnosis. HbA1c was shown to correlate to sCD163 (r=0.36; p < 0.001), sST2 (r=0.22; p = 0.016) and Gal-3 (r=0.2; p = 0.020) in patients with a diabetes duration < 5 years.
sCD163 levels increased in patients with recent-onset type 1 diabetes and the levels increased with higher HbA1c. Patients included in this study will be followed annually until the eventual development of diabetic complications, while continuously studying circulating levels of inflammatory proteins such as sCD163.
1型糖尿病是一种常在儿童期发病的自身免疫性疾病。视网膜病变等并发症常在疾病过程中出现。需要开展研究以确定1型糖尿病并发症的可能预测指标；尤其是能够在并发症发生前很久就识别出风险的标志物。本研究的首要目的是调查儿童和青少年1型糖尿病诊断时血浆中可溶性细胞间黏附分子-163（sCD163）、可溶性生长刺激表达基因2蛋白（sST2）和半乳糖凝集素-3（Gal-3）的水平。第二个目的是在本研究队列中研究它们与糖化血红蛋白（HbA1c）的相关性。
纳入赫尔辛堡医院的1型糖尿病患者（n = 242，年龄0 - 18岁），使用市售的双抗体夹心酶联免疫吸附测定（DuoSet ELISA）和补充辅助试剂盒检测血浆中sCD163、sST2和Gal-3的循环水平。
诊断时的循环sCD163水平显著高于诊断后（分别为666±318ng/ml和505±223ng/ml；p < 0.001）。sST2水平也显著更高（分别为18.2[12.7 - 25.6]ng/ml和9.1[6.3 - 13.5]ng/ml，p < 0.001），但Gal-3水平从糖尿病发病到诊断后并无差异。在糖尿病病程<5年的患者中，HbA1c与sCD163（r = 0.36；p < 0.001）、sST2（r = 0.22；p = 0.016）和Gal-3（r = 0.2；p = 0.020）相关。
近期发病的1型糖尿病患者的sCD163水平升高，且随着HbA1c升高而增加。本研究纳入的患者将每年随访直至最终出现糖尿病并发症，同时持续研究sCD163等炎症蛋白的循环水平。
